This study further defines genetic susceptibility to JIA in the region centromeric to HLA-DRB1. DNA from 234 Finnish JIA nuclear families and 639 elderly Finnish control individuals was genotyped for five functional SNPs within the TAP2 and TAP1 loci (B200 kb centromeric of HLA-DRB1). Subsets of the controls (186) and patients (145) that had been previously typed for HLA-DRB1 were also genotyped by sequence for the HLA-DPB1 locus. Case/control and transmission disequilibrium test (TDT) methods revealed an association with the DPB1*030101 allele for JIA (OR 2.3, 95% CI 1.5-3.5). Notably, a detailed haplotypic analysis of the TAP2/TAP1 loci and their interaction with the HLA-DPB1*030101 and DRB1*08 and *11 alleles showed a variety of over-represented and under-represented TAP2/TAP1 haplotypes not evident in the single marker analysis. The strongest effect was observed in the polyarticular RF negative JIA subgroup for the 2-2-1-2-1 TAP2/TAP1 haplotype (TAP2B and TAP1A alleles) which showed an independent effect from both DRB1*08 and *11 (Po0.000003) and DPB1*030101 (P ¼ 0.02). We have provided evidence that the extended haplotypes (including HLA-DRB1, TAP2/TAP1, and HLA-DPB1) of pauciarticular and polyarticular RF negative disease are distinct. This observation may have implications for functional etiological differences between the pauciarticular and polyarticular JIA patients.
Introduction
At least three regions of the HLA (HLA-A, DR-DQ, and DP) have been reported to show evidence of independent association with JIA (reviewed in Refs. [1] [2] [3] ) leading to theories about the role of antigen presentation and T-cell interaction in JIA disease pathogenesis. The HLA class II region contains over 100 genes in addition to the HLA genes, many of them with demonstrated immunorelevant function. Multiple independent associations in a candidate rich genomic segment suggest that there is a true polygenic susceptibility within the MHC region that remains to be explained. Within the MHC class II region, there also exist at least four polymorphic genes (LMP2, LMP7, TAP1, and TAP2) that are directly involved in antigen processing and transport and that are not structurally related to the DR, DQ, or DP HLA class genes. Other HLA class II related polymorphic sequences involved in antigen processing and presentation are also located in this chromosome region (DMA and DMB). All of these genes are attractive candidates for multilocus susceptibility within the MHC. These genes may have effects on JIA that are additive with or independent from, the DR/DQ or DP loci to which they are linked.
Previous studies of JIA have primarily examined pauciarticular and polyarticular rheumatoid factor negative subsets of disease. The pauciarticular subset in general corresponds to the new JIA classification 4 of persistent oligoarticular disease but may include some patients with the new classification of extended oligoarticular JIA. HLA linkage and association studies have suggested differences in the genetics of pauciarticular and polyarticular subsets but for the most part it is unclear whether these differences reflect different populations studied or true differences in the genetics of susceptibility.
DPB1*0201 association with pauciarticular disease has been described in several populations. [5] [6] [7] [8] [9] [10] [11] [12] [13] However, only four studies have been published to date of DPB1 examination in polyarticular patients. 6, 9, 14, 15 Although these findings suggest a role of HLA-DPB1 in JIA, the magnitude of an HLA-DPB1 effect and the difference in DPB1 susceptibility between pauciarticular and polyarticular patients remains unclear, particularly in light of the stronger DRB1 associations that have been described.
The role of the non-HLA class II genes within the MHC region has received little attention in the study of JIA. Recently, an association of the LMP7 gene was described in which homozygous patients occurred significantly more frequently than homozygous controls at this locus (P ¼ 0.016). 16 This difference remained significant after stratification for DR5 (*11) and DPB1*0201, but no significant functional difference could be discerned in biochemical assays of LMP7 genotypes. 16 Homozygosity of an LMP2 promoter polymorphism showed a weak association with late onset JIA (Po0.05) and with polyarticular patients as a whole (P ¼ 0.05). Because the association remained significant after stratifying the data for the presence of HLA-B27 (not in LD with LMP2), the authors suggested that LMP2 may be important only in children with late-onset disease that is more apt to progress to spondyloarthropathy. 17 The TAP1 and TAP2 gene products, within the MHC class II region, serve as peptide transporters associated with antigen processing and loading onto MHC molecules for cell surface presentation. The three reports using TAP1 and TAP2 polymorphisms in JIA subgroups investigated the concept that change in peptide delivery to a class 1 molecule could alter presentation and result in T-cell response, thereby influencing disease susceptibility. PCR, RFLP, and SSOP were used in those studies and ours to type the single base differences at amino acids 333 and 637 in TAP1 and 379, 565, and 665 in TAP2. Donn et al 18 found association in British patients with the TAP2B allele in early-onset pauciarticular JCA that was independent of previously known LD with DR1 (OR 3.5, 95% CI 1.3-9.7) (which is found in a high frequency of late-onset pauciarticular patients). Ploski et al 19 found an increase in the TAP1B allele in a group of patients of mixed subtypes that, although in strong LD with DR8, was significantly more frequent in DR8-negative patients than in DR8-negative controls. These authors suggested the further subgrouping of at least early-onset pauciarticular patients by TAP alleles for future studies may be relevant in case the pauciarticular subset is itself a very heterogeneous disease. Fernandez-Vina et al 20 found an increase in TAP1B and TAP2B alleles. However, this increase was attributed to suspected LD with the HLA-DRB1*0801 and DPB1*0201 alleles.
We have chosen to examine the DPB1 locus and the TAP polymorphisms to investigate these loci and the haplotypes comprised of them for additional association in a group of Finnish JIA patients. In this study, we examined pauciarticular and polyarticular RF-negative subsets that generally correspond to the current JIA classification of persistent oligoarticular and polyarticular disease. We have previously characterized a 'shared epitope' of JIA susceptibility (DRB1*JIASE) in this group of patients including both subsets, 21 which is defined by the third hypervariable region (HVR) of the HLA-DRB1*08 and *11 alleles. 21 Our previous study also defined differences in marker association between pauciarticular and polyarticular RF negative groups of patients that were localized to the HLA region centromeric of DRB1. In this study, we have used the TAP loci and DPB1 typing results to further investigate the genetic differences of pauciarticular and polyarticular JIA.
Results

DPB1 association
The DPB1 locus showed a strong association in both the pauciarticular and polyarticular RF negative JIA subgroups (P ¼ 0.009 and 0.002, respectively) ( Table 1) . However, this association was less strong than that found for the DRB1 locus (Po0.0003 and o10 À7 , respectively). Of the five major DPB1 alleles in our Finnish samples (comprising 490% of known DPB1 alleles), only the DPB1*030101 allele was significantly over-represented in pauciarticular (23.1% in patients vs 12.4% in controls; P c ¼ 0.03 OR 2.1, 95% CI 1.2-3.7) and polyarticular RF negative patients (25.3% in patients vs 12.4% in controls; P c ¼ 0.0005 OR 2.4, 95% CI 1.5-3.8) (Table 1 ). In patients sharing the DRB1*JIASE genotype, the DPB1*0402 allele frequency was decreased, but did not reach statistical significance (13% in total patients vs 24% in controls; P c ¼ 0.15; OR 0.5, 95% CI 0.3-0.9). In pauciarticular patients that were DRB1*JIASE negative, both DPB1*020102 (38% in patients vs 17% in controls; P c ¼ 0.05; OR 3.0, 95% CI 1.1-5.0) and DPB1*030101 (22% in patients compared with 8% in controls; P c ¼ 0.05; OR 3.4, 95% CI 1.0-7.0) alleles were increased in frequency.
Evidence for independent DPB1 association in pauciarticular JIA Testing for interaction of the DPB1 and DRB1 locus associations in the overall pauciarticular and polyarticular patient groups showed suggestive evidence for independence of the DPB1*030101 allele in pauciarticular (Po0.03; OR 3.3, 95% CI 1.1-9.6) but not polyarticular JIA (Table 2a , b). Additional support for an independent effect of DPB1 was found when the data were conditioned on the DRB1*JIASE-DPB1*030101 haplotype to control for the effect of LD (Table 2c ). DRB1*JIASE and DPB1*030101 were more frequently found on different haplotypes in pauciarticular patients than in controls (P ¼ 0.02; OR 0.22, 95% CI 0.05-0.91). Although there was an apparent difference, the distribution of haplotypes in polyarticular patients did not differ significantly from that in control individuals (P ¼ 0.10; OR 0.34, 95% CI 0.09-1.29). When examined for LD between DRB1 and DPB1, no significant differences in susceptibility alleles were seen between patients and controls and between different phenotypic subgroups among patients.
TAP2/TAP1 haplotypes showed consistent association that was determined by the JIA subtype The five individual polymorphisms of the TAP2/TAP1 loci did not show any consistent pattern or strong association, either within all JIA patients or when subdivided into pauciarticular and polyarticular RFnegative subsets. TAP2/TAP1 haplotypes, estimated from all five TAP SNPs, showed a stronger and more consistent pattern of association with JIA than with each TAP SNP alone ( Table 1 ). The strongest association for the global case-control association and TDT considered together was shown with the pauciarticular subgroup (P ¼ 0.00004; TDT P ¼ 0.0001), while the strongest global association for polyarticular RF-negative patients was in the non-DRB1*JIASE subset (case-control association Po10
À5
). A complex but strong pattern of association was only apparent when estimated haplotypes were stratified for sharing of the DRB1*JIASE genotype (Table 3) . Of the 32 possible haplotype combinations for the TAP SNPs, 22 were identified in patients and control individuals of this study together. Of these 22, six haplotypes comprised over 85% of the haplotypes in both controls and pauciarticular and polyarticular RF-negative subsets of patients.
Pauciarticular patients that shared the DRB1*JIASE genotype and the 2-2-1-2-1 TAP2/TAP1 haplotype were found significantly less frequently than in controls (16% in patients vs 28% in controls; TDT P ¼ 0.03; OR 0.5, 95% CI 0.2-1.0). However, polyarticular patients with the same 2-2-1-2-1 TAP2/TAP1 haplotype, but who did not carry DRB1*JIASE were found far more frequently than in controls (55% in patients vs 28% in controls; TDT P ¼ 0.09; OR 3.1, 95% CI 1.9-5.1).
Likewise, polyarticular patients who did not carry the DRB1*JIASE genotype but shared the 2-2-2-1-2 TAP2/TAP1 haplotype occurred significantly less frequently than in controls (6% of patients vs 18% of controls; OR 0.3, 95% CI 0.1-0.7). The reciprocal was true of pauciarticular patients of the same TAP2/TAP1 phenotype that shared DRB1*JIASE (26% in patients vs 15% in controls; TDT P ¼ 0.0007; OR 2.0, 95% CI 1.0-4.2).
In order to further test the TAP2/TAP1 haplotypes for independent or additive effects to the association of JIA with the DRB1*JIASE and DPB1*030101 genotypes, the TAP2/TAP1 haplotypes were conditioned on the presence of either the DRB1*JIASE or DPB1*030101 genotype (Table 4a , b). The 2-2-1-2-1 haplotype showed evidence for independence from DRB1*JIASE in both subtypes of JIA (pauciarticular OR 0.2, 95% CI 0.04-0.8 and polyarticular OR 0.0, 95% CI 0.0-0.2) and from DPB1*030101 in polyarticular RF negative patients (OR 0.3, 95% CI 0.08-0.8). On the other hand, the 2-2-2-1-2 haplotype showed additive effects to the DRB1*JIASE genotype in patients of both subtypes of JIA (pauciarticular OR 3.7, 95% CI 1.1-12.7 and polyarticular OR 3.3, 95% CI 1.0-10.5). The 2-2-2-1-2 haplotype also had an additive effect with the DPB1*030101 genotype only for polyarticular RF-negative patients (OR 3.1, 95% CI 1.0-9.9). In addition, compared with controls, the 2-2-1-2-1 TAP2/TAP1 haplotype was more likely to occur without DRB1*JIASE and DPB1*030101 on the same haplotype in pauciarticular and polyarticular subtypes of JIA, while the reverse was true of the 2-2-2-1-2 TAP2/ TAP1 haplotype.
There were two other TAP2/TAP1 haplotypes with significant population frequencies (410%) in this study, 2-2-2-2-1 and 1-2-2-2-1. TAP2/TAP1 2-2-2-2-1 was found less frequently in polyarticular patients than in controls (23% in patients vs 33% in controls; OR 0.6, 95% CI 0.5-0.8). The effect of this haplotype was not modified by the DRB1*JIASE genotype (Table 4a ) (OR 0.3, 95% CI 0.1-0.8). TAP2/TAP1 1-2-2-2-1 was found less frequently in pauciarticular patients without DRB1*JIASE than controls (0% in patients vs 9% in controls; TDT P ¼ 0.0004). The TAP2/TAP1 1-2-2-2-1 haplotype was also found more frequently in polyarticular patients sharing DRB1*JIASE than in controls (18% in patients vs 7% in controls; OR 2.9, 95% CI 1.2-7.3). Conditioning this haplotype on DRB1*JIASE showed evidence for additive effects in both subtypes. 
Discussion
This study suggests complex haplotypic associations with JIA within the MHC class two region. The data show effects of: (1) DPB1 alleles, (2) TAP1/TAP2 haplotypes and (3) combined effects of these polymorphic loci and DRB1.
First, in this study JIA is associated with the DPB1*030101 allele in both the polyarticular RF-negative and pauciarticular subsets. However, these associations are less strong than those we have previously reported (and updated here) with HLA-DRB1*08 and *11 combined (HLA-DRB1*JIASE). Interestingly, DPB1*0301 has also been associated with RF-negative adult onset RA. While previous studies using different populations have found independent association of HLA-DPB1*0201 [5] [6] [7] [8] [9] [10] [11] [12] [13] with JIA, we only observed a marginally significant association (P c ¼ 0.05) in non-DRB1*JIASE patients with HLA-DPB1*0201(020102). This may indicate an independent effect of the DPB1*020102 allele in only a particular subset of our pauciarticular patients and/or, less likely, differences in the genetic background of the Finnish population and the other populations previously studied. In addition, we have presented evidence for an independent effect of the DPB1*030101 allele in pauciarticular, but not polyarticular, patients. Our findings are consistent with the DPB1 associations made by other groups studying polyarticular JIA, 6, 9, 11, 14, 15 but not with the findings of other groups for DPB1*0201 susceptibility to pauciarticular JIA.
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12,13,23-26 Our analysis suggests that The TAP2/TAP1 haplotypes are listed in genomic order with the TAP2 alleles preceding the TAP1 alleles (TAP2 379-565-665-TAP1 333-637).
c P-value is corrected for the number of major haplotypes (45%) tested (6) using the Bonferroni method. Second, the current data indicate that the strength of association for the TAP2/TAP1 estimated haplotypes is at least as strong as that observed for the DPB1 locus in both pauciarticular and polyarticular RF-negative disease. We have observed that specific TAP2/TAP1 haplotypes (2-2-1-2-1, 2-2-2-1-2, 2-2-2-2-1, and 1-2-2-2-1) which occur with some frequency in our patient population (410%), have a distinct relationship to DRB1, DPB1, and disease susceptibility (Table 5 ). In addition, because patients with specific TAP2/TAP1 haplotypes are more likely to carry the DRB1*JIASE genotype than controls, DRB1*JIASE is unlikely to be the See footnotes c and d in Table 3 . Odds ratio (OR) could not be calculated due to 0 in the denominator.
only determinant of susceptibility on the DRB1*08 or *11 haplotypes. Likewise, because certain TAP2/TAP1 alleles, which we have associated with specific subsets of JIA, are found more often on different haplotypes than DRB1*JIASE in patients than in controls it is likely that certain TAP2/TAP1 haplotypes (or a gene in LD with it) are independent susceptibility factors for JIA. The alternate explanation for these suggestions is that this analysis reveals a hidden stratification in the controls vs patients that is unrelated to JIA disease. However, no significant difference exists in the overall frequencies of these haplotypes in patients and controls, arguing against an artificial effect of sampling error, which might cause stratification of case and control groups. In addition, the alleles of individual loci are in HardyWeinberg equilibrium in control samples. The strongest evidence for an independent effect of TAP2/TAP1 (or a locus in LD with it) is for the polyarticular group of patients with the 2-2-1-2-1 haplotype (which corresponds to TAP2B and TAP1A alleles of previous studies). This TAP2/TAP1 haplotype is unlikely to have either the DRB1*JIASE or DPB1*030101 on the same extended haplotype. In these polyarticular patients that carry the 2-2-1-2-1 haplotype the DRB1*01 allele is more frequently observed than in controls (50-20%; Po0.00003). A previous study examining HLA in JIA had also implicated DRB1*01 in susceptibility in subsets of JIA patients. 15 However, the strength of association is stronger for the 2-2-1-2-1 haplotype (Po0.000003) than for the DRB1*01 allele (P ¼ 0.005) in the non-DRB1*JIASE patients. Thus, it would appear that the TAP loci or polymorphism(s) in close LD may explain part of the complex genetic effects.
Patients who carry the 2-2-1-2-1 TAP haplotype are much more likely to express the polyarticular RFnegative clinical phenotype of JIA, particularly if they do not carry the DRB1*JIASE genotype. However, TAP haplotype 2-2-2-2-1 (or TAP2A and TAP1A) is clearly reduced in polyarticular patients. This TAP haplotype is also most likely to be carried on a haplotype without DRB1*JIASE or DPB1*030101, a characteristic it shares with control individuals with respect to DPB1*030101 but not DRB1*JIASE. Therefore, people carrying the 2-2-2-2-1 haplotype on the same haplotype as DRB1*JIASE are least likely to be affected by polyarticular JIA.
Our data also suggest that the 2-2-2-1-2 TAP haplotype (TAP2A and TAP1B) has a strong additive effect to DRB1*JIASE in pauciarticular JIA, but is not an independent factor in susceptibility. The same is true for the 1-2-2-2-1 (TAP2C/TAP1A) haplotype in polyarticular patients.
One possible interpretation of the data in this study is that specific TAP2 or TAP1 alleles, that are part of the JIA-associated haplotypes, may be associated with different disease phenotypes. TAP2A is under-represented in polyarticular disease, and over-represented in pauciarticular JIA. This suggests that the presence of TAP2A is a marker for haplotypes that distinguish the pauciarticular from polyarticular RF-negative clinical phenotypes. Likewise, TAP1B, that is a part of the haplotype conferring susceptibility to pauciarticular disease, may be the critical susceptibility allele in this region. This allele was previously found to show susceptibility to JIA in a mixed population of subtypes. 19 However, that study did not distinguish whether this effect of TAP1 was independent of TAP2.
The two other previous studies, which examined JIA association with TAP alleles, in contrast to our results, found associations with TAP2B with pauciarticular disease. 18, 20 However, the sample size of their studies was limited (29 and 52 patients, respectively) and associations were not as strong as those reported here.
Each of the TAP SNPs that we have analyzed codes for functional amino-acid substitutions in the proteins.
27-29
The TAP1 and TAP2 genes encode peptide transporters that aid in the preparation for peptide presentation by class I, and not class II, MHC molecules. The findings of independent and additive susceptibility in these TAP loci suggest that we and others have observed that the MHC class I system is involved in JIA disease etiology. Additional evidence supporting class I involvement is provided by the independent associations that have been observed for the HLA-A2 allele and by recent findings of susceptibility loci in the class I region. 30 Finally, it is worth noting that the DPB1*030101 allele is not in strong LD with the TAP2/TAP1 haplotypes 2-2-1-2-1, 2-2-2-1-2, and 2-2-2-2-1, that also confer susceptibility for different subsets of JIA. Thus, this supports the general conclusion that the association of different JIA subsets reflects more than a single susceptibility locus.
A recombination hotspot between DR/DQ and DP has been characterized and is located within the TAP2 gene. [31] [32] [33] Depending on where additional JIA susceptibility loci are located with respect to the recombination hotspot, the association of a strong class II haplotype with disease might imply very strong selection across loci in LD to balance the disruptive effects of recombination. Although LD is apparently not a very good predictor of crossover frequency, 32 it seems likely that selection has played a role in generating and maintaining JIA associated class II haplotypes in the face of this childhood disorder. In the case of JIA, there appears to be at least two regions of strong susceptibility (DRB1 and TAP/DPB1) and the presence of high recombination frequency near the TAP2 locus may have at least contributed to generating the haplotypes associated with disease in this study and in maintaining the overall haplotype diversity found in this region.
This study provides a clearer definition of the association of JIA with haplotypes including HLA-DR/ DQ, TAP, and HLA-DP alleles and should lead to a better understanding of the genetics of this disease(s). The interaction of these genes within the MHC region may Each row lists the most likely alleles at the DRB1, TAP, and DPB1 loci that are contained on the indicated susceptibility haplotype. Dashes indicate the absence of either DRB1*JIASE or DPB1*030101, respectively. Susceptibility in pauciarticular patients may be due to the presence of either TAP2A/TAP1B on the haplotype with DRB1*JIASE and/or the presence of DPB1*030101.
have led in part to the conservation of certain class II haplotypes due to functional constraints and selective forces; however, the current observations may also be constrained by the genetic relationships and LD within the Finnish population. Our data indicate that there is a complex relationship of loci/genes within the MHC class II region conferring susceptibility to distinct genetic subtypes of JIA and dependent on the interaction of multiple gene families affecting immune function.
Materials and methods
Patient and control samples
The ethics committee of the Rheumatism Foundation Hospital in Finland approved this study and the patients/parents gave informed consent to participate in the study. Genomic DNA samples of JIA patients were collected at the Rheumatism Foundation Hospital in Finland. DNA samples from Finnish proband family trios and from controls were prepared from buccal cell swabs or extracted from peripheral blood as previously described. 34 Sample DNA concentrations were determined using a PicoGreen fluorescence assay (Molecular Probes). The Rheumatism Foundation Hospital receives patients from all the five university hospitals in Finland and from the remaining 16 central hospital districts, but particularly in the middle-eastern region where the Rheumatism Foundation Hospital is located. It is estimated that about 2/3 of all Finnish JIA patients are seen at the Rheumatism Foundation Hospital at some time during disease course. Patients in this study series included only those constantly monitored by the Rheumatism Foundation Hospital. This group consisted of 234 proband patient samples and 393 parent samples (184 fathers and 209 mothers) as well as samples from 57 siblings of probands. Of the probands, 57 were male and 178 were female. In all, 150 probands had onset of disease symptoms before the age of six. The 82 pauciarticular onset and 152 polyarticular RF-negative onset probands were classified according to the criteria of Brewer et al. 35 Although not exactly correct in its correspondence with term juvenile rheumatoid arthritis, the disease is herein called juvenile idiopathic arthritis (JIA). Probands all tested negative for RF, and HLA-B27-positive individuals were excluded from the analysis. HLA-B27-positive individuals have a high probability of developing spondyloarthropathy at a later age and may not be appropriately classified as polyarticular or pauciarticular JIA. Finnish control individuals were all 65 þ years of age, randomly selected from the population and survived without history of JIA or RA.
DRB1 and DPB1 typing
Most of the individuals in this study had been previously typed for the HLA-DRB1 locus. 21 The DPB1 and DRB1 loci were typed using AlleleSEQR HLA-DRB1 and AlleleSEQR HLA-DPB1 Sequencing-Based typing kits (Forensic Analytical, Hayward, CA 94545) according to the manufacturer's instructions for the ABI 3700 DNA Analyzer. This method directly sequences exon 2 of each gene. Sequence analysis was performed using the supplied ABI software (SeqEd, Matchtools, and MT Navigator).
Marker selection
The TAP1 and TAP2 markers used in this study were selected from one primary source. 29 The five SNP markers were adapted for the ABI SNaPshot detection system (ABI) using the primer sequences and the genomic sequence contained in Genbank (http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?cmd ¼ Retrieve&db ¼ nucleotide&list_uids ¼ 34634&dopt ¼ GenBank).
PCR PCR amplification for all markers was performed in 384-well plates for 30 cycles using 0.5 ml PCR buffer, 0.7 ml 2.5 mM dNTP mix (Pharmacia & Upjohn), 0.05 ml cDNA polymerase (Clonetech Advantage), 0.1 ml 10 mM flourescently labeled primer mix, 2.65 ml double-distilled H 2 O, and 1 ml 0.2 mg/ml genomic DNA for a 5 ml total reaction volume. Reactions were placed in a PE thermal cycler for 2 min at 951C; 30 cycles of 45 s at 941C, 45 s at 571C, and 1 min at 721C; and a final extension of 7 min at 721C.
Initial amplification for the SNP markers was performed as per Powis et al. 29 All initial amplification was performed at 601C. TAP2/TAP1 haplotypes consisted of the five biallelic TAP markers genotyped in this study. The nomenclature for the TAP haplotypes used in this analysis reflects the state of all five markers from 5 0 to 3 0 (eg-'2-2-1-2-1'). Alleles one and two of each marker were assigned in alphabetical order. Thus haplotype 2-2-1-2-1 represents nucleotides G-G-A-G-A.
Genotyping PCR-amplified product (B0.5 ml) of each microsatellite and insertion/deletion marker was run on the ABI 3700 DNA Analyzer.
We used the ABI Prism SNaPshot Multiplex System (ABI Prism SNaPshot Multiplex Kit, ABI #4323151) for genotyping single-nucleotide polymorphisms (SNPs). The SNaPshot assay is a single base extension protocol designed to genotype SNP markers using the ABI Prism 3700 DNA Analyzer. We multiplexed up to seven different SNP assays in one single base extension reaction. PCR primers were designed to amplify the SNP containing regions and varied in the length of the PCR product for each SNP (100-800 bp). PCR products for each sample were then mixed into a single tube in equal volumes. ExoSAP-IT (usb #78200) was used at 2 ml for each 5 ml PCR reaction mix to remove excess dNTPs and primers to obtain a purified template. Single base extension reactions were performed in 3 ml reaction volumes per sample. A volume of 1 ml of cleaned PCR template was combined with 1.5 ml of the SNaPshot Multiplex Ready Reaction Mix and 0.5 ml of a mix of primers for each SNP. The single SNP primer for each SNP assay was designed in either the forward or reverse direction using conventional primer design programs that minimize primer dimer and loop formation. We adjusted the final product size of each assay using the 5 0 addition of a poly A tail. C is substituted within the added poly A tail to reduce loop and dimer formation of the final primer. The concentration of the SNP primer was used to adjust the relative strength of signal in the final amplified products. Our initial SNP primer concentration was taken as 0.1 mM for each assay and then adjusted accordingly. After thermal cycling, unincorporated ddNTPs were removed with the addition of 1 ml SAP to the 3 ml primer extension reaction. Samples were then run on the 3700 DNA Analyzer with 1 ml of product in combination with GeneScan-120 LIZ size standard (ABI #4324211) at a 1 : 200 dilution in 4 ml of formamide. Data collection on the 3700 DNA Analyzer were performed using a run module modified from a default module (GeneScan2_POP6DefaultModule) to include a cuvette temperature of 501C, a shortened run time of 2100 s and a run delay of 900 s, no flat-field correction, and foil piercing disabled. SNP data were analyzed using the GeneScan and Genotyper software from ABI. When specific alleles were examined, the Bonferroni corrected P values (P c ) based on the number of common alleles or haplotypes (45%) are provided. No adjustments were made with respect to the number of genetic loci examined. Appropriate adjustments of nominal levels of significance are difficult since each gene has been suggested by previous studies and the genes exhibit a complex pattern of linkage disequilibrium. When associations are marginal (P40.001) the results should be considered as exploratory or suggestive.
Analysis
Odds ratios (ORs) were calculated by the MantelHaenszel odd ratio and 95% confidence interval available at the 'EPITOOLS-Epidemiology Tools on the Net' website on the Internet (http://www.medepi.org/epitools/rfunctions/ormh.html). Analysis by TDT was performed using FBAT. 37, 38 The TAP2/TAP1 haplotypes are named by the genomic order of the markers with the TAP2 alleles preceding the TAP1 alleles (TAP2 379-TAP2 565-TAP2 665-TAP1 333-TAP1 637). Haplotypes using combinations of all markers were estimated using the PHASE program. 39 D 0 values were calculated from the estimated haplotype frequencies generated in PHASE and permuted P-values for linkage disequilibrium (LD) at the locus level were calculated from the unphased genotypic data using the program ARLEQUIN (http:// anthro.unige.ch/arlequin). Permuted P-values calculated with the estimated haplotypes generated by PHASE did not differ significantly from those generated using unphased genotypic data.
Testing for additive effect in unlinked loci was performed after the method of Svejgaard and Ryder. 40 Testing for independent effects controlling for linkage disequilibrium in linked loci was performed by using estimated haplotypes to count the number of individuals who had the alleles in question on the same or different haplotypes. w 2 analysis and Odds Ratio were calculated for comparisons of two groups.
